NAVIGATOR trial investigators call for closer attention to glucose levels in cardiovascular and diabetes at-risk patients Part 4
References “Valsartan Reduces the Incidence of Atrial Fibrillation within the Patients beside Heart Failure in the Val-HeFT conduct tests.” Abstract presented at ESC 2003.
About Novartis Novartis AG (NYSE: NVS) be a world editorial column in pharmaceuticals and client durability. In 2003, the Group’s business achieve sale of USD 24.9 billion and a frame takings of USD 5.0 billion. The Group invest just about USD 3.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group company take into service in the territory of 80 000 ethnic group and operate in done 140 land in a circle the world. For further reports oblige consult Disclaimer The foregoing unshackle encompass forward-looking dispatch note that can be identified by means of language such in support of “potential” “investigating”, “new applications”, or analogous expressions, or by debate in connection with forthcoming strange certification or labeling in support of Diovan, Starlix, or regarding the long-term impact of a patient’s using sentient of any article of trade. Such forward-looking statements need specified and unknown speculate, uncertainties and other factor that may grounds actual grades with Diovan or Starlix to be materially at probability from any wished-for results, celebration or feat expressed or implied by such statements. There can be no support that Diovan or Starlix will be accepted for any spare indications or labeling in any open market. In exacting, management’s facility to ensure cheer of the health authorities’ further requirements is not guaranteed and management’s expectations regarding commercialization of Diovan or Starlix could be extravagant by, among other things, additional analysis of Diovan or Starlix clinical transcript; new clinical data; hasty clinical trial results; unexpected regulatory engagements or delay or affairs of put across restraint mostly; the company’s ability to land or assert government grant or other proprietary intellectual goods safety; spite largely; and other risks and factors referred to in the Company’s newsworthy Form 20-F by the side of guide with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying deduction prove wrong, actual results may rise and fall materially from those anticipated, believed, implicit or appointed. Novartis is providing the information here clutch release launch this date and do not embark upon any constraint to update any forward-looking statements contained in this press release by this means of new information, future actions, or otherwise.
(2) Nauck MA, Duran S, Kim D, Johns D, Festa A, Trautmann M. Effects of exenatide associate with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulphonylurea and metformin. Data disclosure at the 42nd annual gathering of the European Association of the Study of Diabetes. September 14, 2006.
